Investment
Features
FeesSafety
Academy
More
Pluang+

Chicago Atlantic Real Estate Finance merger to lower dividend yield but keep it attractive at 15-16%.

Market News
18 Sep 2026
Seeking Alpha
View Source
Neutral
Chicago Atlantic Real Estate Finance merger to lower dividend yield but keep it attractive at 15-16%.

Chicago Atlantic Real Estate Finance (REFI) is merging with Chicago Atlantic BDC (LIEN) in a NAV-for-NAV deal with an exchange ratio of about 1.085 LIEN shares per REFI share. Both stocks currently trade at a 23% discount to NAV. Post-merger, the quarterly dividend is expected to be $0.37–$0.40, yielding 15–16%, which is lower than the current 17% but still considered attractive. The merger preserves REFI's earning power, with potential upside from better deployment and synergies, although it does not significantly increase per-share earnings.

Chicago Atlantic Real Estate Finance's merger news comes as context for readers following real estate stocks. For readers following real estate stocks, here is Pluang's market snapshot as of Sep 18, 2026 19:12 WIB: Among 25 priced US real estate stocks tradable on Pluang, 15 rose and 8 fell today. Notable movers include BEKE (KE Holdings Inc) up 1.63% to USD 16.26 with a typical hold time of 21 days, PLD (Prologis Inc) down 1.26% to USD 133.48 with a typical hold time of 101 days and 91% sell order activity, and EPR (EPR Properties) up 0.82% to USD 57.63 with a typical hold time of 39 days.

More News

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
32 minutes ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
46 minutes ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
1 hour ago
Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays cuts Lennar price target to $70 amid weak Q3 earnings and housing market challenges

Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...

Analyst Insights
Bearish
2 hours ago
Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim raises price target for Restaurant Brands International to $86 amid growth and share buybacks

Guggenheim has raised its price target for Restaurant Brands International (QSR) to $86 from $85 and reiterated a Buy rating, reflecting confidence in the company's strategic growth. Restaurant Brands International is enhancing shareholder value thro...

Analyst Insights
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App